KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) FCF Margin (2016 - 2025)

Vertex Pharmaceuticals has reported FCF Margin over the past 17 years, most recently at 10.93% for Q4 2025.

  • Quarterly results put FCF Margin at 10.93% for Q4 2025, down 597.0% from a year ago — trailing twelve months through Dec 2025 was 26.61% (up 3378.0% YoY), and the annual figure for FY2025 was 26.61%, up 3378.0%.
  • FCF Margin for Q4 2025 was 10.93% at Vertex Pharmaceuticals, down from 37.04% in the prior quarter.
  • Over the last five years, FCF Margin for VRTX hit a ceiling of 49.47% in Q2 2022 and a floor of 144.49% in Q2 2024.
  • Median FCF Margin over the past 5 years was 40.58% (2022), compared with a mean of 25.45%.
  • Biggest five-year swings in FCF Margin: crashed -18760bps in 2024 and later skyrocketed 17577bps in 2025.
  • Vertex Pharmaceuticals' FCF Margin stood at 45.03% in 2021, then rose by 1bps to 45.37% in 2022, then tumbled by -85bps to 7.01% in 2023, then surged by 141bps to 16.9% in 2024, then tumbled by -35bps to 10.93% in 2025.
  • The last three reported values for FCF Margin were 10.93% (Q4 2025), 37.04% (Q3 2025), and 31.28% (Q2 2025) per Business Quant data.